BBOT at a glance
BridgeBio Oncology Therapeutics Inc (BBOT, SEC CIK 1869105) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Oncology Therapeutics Inc (BBOT) reported revenue of $11.3 million (up 77.9% from FY2024) and a net loss of $134.0 million. Diluted EPS was -$4.30.
- As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding BridgeBio Oncology Therapeutics Inc (BBOT) shares worth $54.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Beltran Pedro on November 18, 2026 of 1,870 shares at $1.84 per share.
- In the last 90 days, BBOT insiders reported 0 open-market purchases ($0) and 2 open-market sales ($4K) on Form 4, a net sale of $4K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $11.3M
- +77.9% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$4K
- 13F holders
- 16 funds
- $54.8M · +0 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- No product revenue in Q3 2026 or Q3 2025, reflecting clinical-stage status
- Operating margin not applicable, operating loss $37.5M vs $49.2M YoY
- R&D strongest focus: $29.6M, down 16% YoY; trial and consumables expenses $20.1M
- Cash, equivalents and marketable securities $315.3M at September 30, 2026, expected to fund at least twelve months
- Operating cash outflow $108.6M vs $71.7M YoY; $500.0M shelf and $200.0M ATM established, with no ATM sales by quarter-end
Risk Factors
- Newly triggered supply-chain risk: BIOSECURE Act enacted December 18, 2025 could restrict Chinese sole-source suppliers
- Most material regulatory update: FDA leadership changes and post-July 2024 Supreme Court ruling increase approval uncertainty
- Clinical risk: Phase 1 trials for BBO-8520, BBO-10203 and BBO-11818 may fail to demonstrate safety or efficacy
- Competitive risk: Two FDA-approved KRASG12C inhibitors compete directly with BBO-8520
- Liquidity risk: Existing cash, cash equivalents and marketable securities expected to fund operations into 2029, not regulatory approval of candidates
AI summary of the BBOT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces BBOT financial results for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed quarterly results and management commentary
Item EX-99.1: Item EX-99.1
- BBO-8520 plus pembrolizumab achieved 75% ORR at 500 mg QD and 53% across doses in 2L+ KRAS G12C inhibitor-experienced NSCLC
- BBO-8520 monotherapy delivered 63% ORR and 100% DCR in 41 inhibitor-naïve NSCLC patients, supporting differentiated efficacy potential
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Medical and Development Officer Yong Ben, M.D., M.B.A. resigning effective January 8, 2027
- Departure not related to disagreements over company operations, policies, or practices
Item 8.01: Other Events
- September 8, 2026 press release highlights new BBO-8520 data and strategic focus on 2L+ NSCLC combinations
- Pipeline emphasis includes BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers
Item EX-99.1: Item EX-99.1
- BBO-8520 plus pembrolizumab produced 75% ORR at 500 mg QD in 2L+ NSCLC after prior KRAS G12C inhibitor treatment
- BBO-8520 monotherapy delivered 63% ORR and 100% DCR in 41 previously untreated 2L+ NSCLC patients
Item EX-99.2: Item EX-99.2
- BBOT prioritizing BBO-8520 plus pembrolizumab in post-G12C NSCLC, while deprioritizing 1L NSCLC development and further BBO-8520 investment there
- BBO-8520 combination delivered 75% ORR at 500 mg QD and 53% across doses in 17 G12C inhibitor experienced patients
AI summaries of BBOT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BBOT
Don't miss the next BBOT filing
- Alerts as it files. A push when BBOT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BBOT, by share count.
- Ask anything. An AI agent that reads every BBOT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Beltran Pedro | Sell | Nov 18, 2026 | 1,870 | $1.84 |
| Cobo Marc | Sell | Nov 13, 2026 | 78 | $2.37 |
| Cobo Marc | F | Oct 21, 2026 | 203 | $2.68 |
| Elmelech Idan | F | Oct 1, 2026 | 343 | $3.94 |
| Beltran Pedro | F | Oct 1, 2026 | 1,047 | $3.94 |
| Ben Yong | F | Oct 1, 2026 | 1,047 | $3.94 |
| Cobo Marc | F | Oct 1, 2026 | 126 | $3.94 |
| Cobo Marc | F | Sep 10, 2026 | 203 | $5.52 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $6.4M | $11.3M |
| Operating Income | -$42K | -$584K | -$145.8M |
| Net Income | -$42K | $7.6M | -$134.0M |
| Op. Margin | - | -9.2% | -1285.5% |
| Net Margin | - | 119.2% | -1181.7% |
| Balance Sheet | |||
| Total Assets | $333K | $194.4M | $448.4M |
| Equity | -$64K | -$3.7M | $411.1M |
| ROE | 65.6% | -203.6% | -32.6% |
| Per Share | |||
| EPS | - | $-5756.41 | $-4.30 |
| Cash Flow | |||
| Operating CF | - | -$764K | -$113.9M |
| CapEx | - | $49K | $606K |
Source: XBRL data in BridgeBio Oncology Therapeutics Inc (BBOT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BBOT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 16 | $54.8M |
| Q2 2026 | 16 | $89.6M |
| Q1 2026 | 13 | $85.6M |
| Q4 2025 | 14 | $124.9M |
| Q3 2025 | 11 | $112.7M |
- BlackRock+1.86M (+86%)
- Goldman Sachs Group+137.5K (+135%)
- Citadel Advisors LLC+79.3K (+3%)
- Millennium Management+39.0K (+37%)
- Morgan Stanley+35.5K (+1051%)
- Northern Trust−161.5K (-87%)
- State Street Corp−143.3K (-14%)
- Bank of America Corp−26.3K (-34%)
- Vanguard Capital Management LLC−14.6K (-1%)
- Citigroup−9.0K (-45%)
- Dimensional Fund Advisors+52.4K
- Ameriprise Financial+35.9K
- FMR LLC (Fidelity)−240.6K
- Two Sigma Investments−26.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 70 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BBOT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | - | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BBOT SEC filings: frequently asked questions
Are BBOT insiders buying or selling?
In the last 90 days, BridgeBio Oncology Therapeutics Inc (BBOT) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $3,628 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BBOT stock?
As of September 30, 2026, the largest BridgeBio Oncology Therapeutics Inc (BBOT) holders among the 13F filers tracked by SignalX were BlackRock ($16.4 million), Alphabet Inc ($11.6 million), Citadel Advisors LLC ($11.1 million), Vanguard Capital Management LLC ($8.2 million), State Street Corp ($3.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BBOT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Oncology Therapeutics Inc (BBOT) reported revenue of $11.3 million (up 77.9% from FY2024) and a net loss of $134.0 million. Diluted EPS was -$4.30. The figures come from the XBRL data in the 10-K.
What did BBOT report in its latest 8-K?
BridgeBio Oncology Therapeutics Inc (BBOT) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces BBOT financial results for quarter ended September 30, 2026.
What are the latest BBOT SEC filings?
BridgeBio Oncology Therapeutics Inc (BBOT) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 20, 2026.
What is BBOT's SEC CIK number?
BridgeBio Oncology Therapeutics Inc (BBOT)'s SEC Central Index Key (CIK) is 1869105. EDGAR lists every BBOT filing under that number.
Ask anything about BBOT
The research agent reads BBOT's filings, financials, insider trades and 13F holders, then answers with sources.